Ironwood Pharmaceuticals, Inc. updated financial guidance for the full year 2021. For the year, company expects total revenue at the High end of $390 million to $410 million against previous guidance of $390 million to $410 million.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
7.75 USD | -1.65% | -6.74% | -32.26% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-32.26% | 1.25B | |
+0.17% | 42.86B | |
+10.92% | 42.74B | |
+44.30% | 41.36B | |
-6.20% | 27.68B | |
+5.23% | 25.15B | |
-24.79% | 18.63B | |
+26.69% | 12.37B | |
-3.13% | 11.92B | |
+6.57% | 11.21B |
- Stock Market
- Equities
- IRWD Stock
- News Ironwood Pharmaceuticals, Inc.
- Ironwood Pharmaceuticals, Inc. Updates Financial Guidance for the Full Year 2021